Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
300 participants
Study Classification
INTERVENTIONAL
Study Start Date
2013-06-30
Study Completion Date
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Currently there is debate in the literature as to the recommended length of postoperative antibiotics in patients undergoing orthognathic surgery. The investigators plan to investigate using a randomized controlled trial the comparison between a 1 day and 3 day regimen of antibiotics and the effects on post operative infection.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antibiotics for Prevention of Infection Following Orthognathic Surgery
NCT05852158
Orthognathic Surgical Site Infection
RECRUITING
PHASE4
Antibiotic Prophylaxis in Rhinoplasty
NCT04194216
Nasal Obstruction
Nasal Surgical Procedures
ENROLLING_BY_INVITATION
PHASE3
The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery
NCT01912651
Facial Defect
RECRUITING
PHASE4
Antibiotics in Free Flaps Reconstructions
NCT02436083
Postoperative Infection
COMPLETED
PHASE4
Postoperative Antibiotics Following Primary and Secondary Breast Augmentation
NCT04834310
Surgical Site Infection
Capsular Contracture Associated With Breast Implant
Antibiotic Resistant Infection
+1 more
WITHDRAWN
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Capital Health Research Ethics Board Orthognathic Surgery and Postoperative Antibiotic Use Protocol
Background, Rationale and Statement of Research Question(s):
Surgical site infection is a potential problem with any surgical procedure. Surgical procedures done through the oral cavity are at a higher risk due to the presence of bacterial pathogens. Orthognathic surgery, involves incising through oral mucosa and creating osteotomies in underlying bony structures. Of the potential complications that can arise from this surgery, post operative infection (POI) is the most common. POI can have a significant impact on surgical outcomes and are associated with an increased cost to the health care system. The literature is quite clear on the benefits of presurgical prophylactic antibiotics in reducing the rate of post operative surgical site infections.1 Currently there is conflicting literature as to the recommended length patients should receive antibiotics during the postoperative course, and the majority of studies have small sample sizes.2,3
Orthognathic surgery is considered a clean-contaminated surgery with a suspected POI rate of 10-15%.2 In 1999 Bentley et. al conducted a randomized control trial comparing 1day vs 5day regimen of antibiotics following orthognathic surgery.4 This trial was stopped due to the drastic difference seen between the two groups, 6.7% in the 5 day course compared with 60% seen in the 1 day group.4 This data varies greatly from the rates of infection that the investigators have seen in their department using a 1 day course of antibiotics. Chow et al. in 2007 did a retrospective chart review of complications seen in orthognathic surgery. They found the rate of infection was significantly decreased by continuing antibiotics in the post operative course when compared to using only one prophylactic dose. They found the infection rates to be 17.3% with a single preoperative IV dose, 5.1% with a pre-operative dose and 2 days post-operative, and 7.7% with a pre-operative dose and 3 days of post-operative antibiotics.5 They also found no significant difference in rates of infection comparing 2 days and up to 14 days.5 A meta-analysis by Danda et al. in 2011 found that a regimen consisting of a single dose of preoperative antibiotics followed with an extended term postoperatively is the most effective in decreasing surgical site infections. They found the incidence decreased by 3.2 times, with the greatest effect noted with administration for 2 days.2 Even in this meta-analysis the average number of patients in each of the 8 studies was 67, with the total number of patients included being 532.2 This shows the need for randomized controlled studies with large sample sizes in order to determine the best antimicrobial regimen for these patients. The majority of studies investigating the rates of infection in orthognathic surgery use penicillin as the antibiotic of choice due to its spectrum of coverage for oral microbes and it is reasonably tolerated by patients.2,4-8 In the investigators department cefazolin is the antibiotic of choice and lower rates of infection have been observed compared to penicillin. The investigators suspect the lower rates of infection with cefazolin is due to the increased gram negative coverage and better resistance to beta lactamases. This has influenced the investigators decision to use first generation cephalosporins instead of penicillin as first line antimicrobials. In patients allergic to penicillin, clindamycin is used. The criteria for diagnosis of infection will follow the CDC guidelines for SSI. The primary outcome is to determine if there is any benefit to extending antimicrobials in the postoperative course following orthognathic surgery. Secondary outcomes include comparing the rates of infection between cefazolin/cephalexin groups and the clindamycin groups, and the rate of infection with different surgical procedures.
Currently at the CDHA the standard perioperative antimicrobial regimen for orthognathic surgery patients is one preoperative prophylactic dose of 2g of IV cefazolin followed by 1g IV every 8 hrs for 3 doses. Patients with an allergy to penicillin receive one preoperative prophylactic dose of IV Clindamycin 600mg, followed by 600mg IV every 8 hrs for 3 doses.
The investigators plan to conduct a double blind randomized controlled trial comparing the effect of a single day of post operative antibiotics with an extended 3 day course of antimicrobials on the infection rate. Both groups will receive an IV prophylactic dose followed by 3 IV doses postoperatively. Group 1 will then receive PO antibiotics for 2 subsequent days following IV treatment, and group 2 will receive a PO placebo.
A placebo will be used in order to blind the two groups so that the patient, surgeon and investigators are not aware of which patients are receiving the extended regimen of antibiotics. This will avoid potential bias in the patient report of symptoms or side effects, and the surgeon's bias in diagnosis of surgical site infection.
Subject Selection:
All patients over the age of 16 years undergoing orthognathic surgery at the QEII VG hospital are eligible to participate in the study. All surgeons operating at the VG site have been asked to include their patients in this study. These include patients undergoing either isolated Lefort I osteotomy, bilateral sagittal split osteotomies, functional genioplasties, or any combination of the three procedures. Wisdom teeth, if present, will also be extracted at the time of the surgery. Exclusion criteria include use of antibiotics in the past 2 weeks, active oral or odontogenic infection, significant medical condition, or if the patient is immunocompromised. All patients will have history and physical examination, CBC, INR/PTT, electrolytes as well as a radiographic evaluation prior to surgery. A power analysis was done to determine the required patient sample size for this study. This was done using a 5% change in infection as clinically significant and type I error of 0.05 with 0.90 power. The sample size required would be 397 patients. The investigators would like to enroll as many as possible over the next 2 years and anticipate to enroll approximately 500 patients. Study enrollment will finish in 2 years time from starting date, unless required sample size has not been met at which time it may be decided to extend length.
Research Plan:
All patients enrolled in the study will receive the standard preoperative IV prophylactic antibiotic, followed by 3 IV doses postoperatively. The patients will be randomly allocated to either the placebo or the antibiotic group at their presurgical assessment appointment. This allocation will be done by a clinical nurse, patients will be given a study patient number and handed a envelope from a folder that has been mixed sufficiently, inside this envelope will be a paper with an A or B denoting to the Shoppers Drug Mart pharmacy on the main floor of the VG hospital to dispense the according bottle they are to receive. This will be recorded beside their study number, and not be unblinded until the study is concluded. Blinding is important to avoid bias in assessment of infection by the surgeons, and to avoid bias in reporting of symptoms of either infection or side effects from the antibiotics. Following the completion of the IV antibiotic regimen, group 1 will receive oral cephalexin or clindamycin four times per day for 2 days and group 2 will receive a placebo four times per day for 2 days. All patients will also be sent home with specific oral hygiene instructions in addition to chlorhexidine 0.12% rinse to be used for 2 weeks postoperatively.
Patients will be assessed for signs of infection and recovery progress daily during hospital stay and during regular recall visits at 2 weeks and 4 weeks following discharge. There is no additional time requirements or cost to the patient by participating in this study. The diagnosis of infection will be made according to the CDC criteria of surgical site infection which include: purulent drainage, wound culture for known pathogen, at least one of signs or symptoms of infection (pain, tenderness, localized swelling, redness or heat)1.
The patient may withdrawl from the study at any time. A patient may be removed from the study if there is a significant change in the patients medical condition. An interm review of the rates of infection will be done and if the data demonstrates an increase risk to patients participating in study, the study will be stopped and unblinded.
All adverse events, serious adverse events, adverse drug reations will be reported to the Oral Maxillofacial Surgery Department and the patient will be assessed by the resident or attending surgeon.
Analysis of Data
All of the data will be organized and pooled according to each specific group. Following the study the blinding will be undone, and the primary outcome investigating the rate of infection will be analyzed in each of the four groups, 1 day cefazolin, 3 day cefazolin/cephalexin, 1 day clindamycin, 3 day clindamycin. Each of the 1 day groups will be compared and the 3 day groups in order to determine if the length of time on antibiotic has an effect on the rate of infection. Then the 1 day group and 3 day groups will be compared for the different type of antibiotic to see if the type of antibiotic has bearing on the length required. These comparisons will be done using a chi squared formula to look for statistical significance. This analysis will also be used to compare rates of infection between the type of surgical procedures done. Each of the groups will also be analyzed for possible confounding factors including time of surgery, age, sex, and oral hygiene status.
Confidentiality
All data will be kept secure by the research team by storing it in a locked office filing cabinet, or on a password protected file on the secured hospital network. Only the investigators, and research nurse will have access to this data. Following the study, the data will be kept in a locked cabinet for at least 25 years as required by law.
Harms
As all patients will receive the standard current protocol used at the investigators center, with the test group receiving an addition 2 days of antibiotics. The risks associated with participation in the study are those seen from prolonged antibiotic use. These include allergic reactions ranging from rash to anaphylaxis, toxic reactions to kidney, liver, gastrointestinal and secondary infections from candida or resistant pathogens. If anaphylaxis occurs normal protocol will be followed for treatment and monitoring. In the event of other adverse events from the antibiotic it will be stopped and any secondary infections will be treated appropriately. In the case of post operative infection this will be treated with a 10 day course of appropriate antibiotics.
Benefits
Overall the benefit of this study is to determine the ideal length of postoperative antibiotics in preventing post operative surgical site infections in patients undergoing orthognathic surgery. The group receiving an extended course of antibiotics potentially may have a lower rate of infection. Conversely, the placebo group may have the same rate of infection and avoid potential side effects of extended antibiotic treatment.
Disclosure of Any Financial Compensation
There will be no monetary compensation for participation in this study. Either the antibiotic or the placebo will be provided to the patient at no cost.
References
1. National Center for Infectious Diseases, Mangram AJ, Horan TC, Pearson ML, et. al. Guideline for Prevention of Surgical Site Infection, 1999. Infection Control and Hospital Epidemiology, 20:4:247- 278, 1999
2. Danda AK, Ravi P. Effectiveness of Postoperative Antibiotics in Orthognathic Surgery: A Meta-Analysis. J Oral Maxillofacial Surgery 69:2650-2656,2011
3. Tan SK, Lo J, Zwahlen RA. Perioperative Antibiotic Prophylaxis in Orthognathic Surgery: A Systematic Review and Meta-Analysis of Clinical Trials. Surg Oral Med Oral Pathology Oral Radiology Endodontics 112:19-27, 2011
4. Bentley KC, Head TW, Aiello GA. Antibiotic Prophylaxis in Orthognathic Surgery: A 1-Day Versus 5-Day Regimen. J Oral Maxillofacial Surgery 57:226-230.1999
5. Chow LK, Singh B, et al. Prevalence of Postoperative Complications After Orthognathic Surgery: A 15year Review. J Oral Maxillofacial Surgery 65:984-992, 2007
6. Ruggles JE, Hann JR, Antibiotic Prophylaxis in Intraoral Orthognathic Surgery. J Oral Maxillofacial Surgery 42:797-801, 1984.
7. Fridrich KL, Partnoy BE, Zeitler DL. Prospective analysis of Antibiotic Prophylaxis for Orthognathic Surgery. International Journal Adult Orthodontic and Orthognathic Surgery 9:129-131, 1994
8. Jansisyanont P, Sessirisombat S, Sastravaha P, Bamroong P, Antibiotic Prophylaxis for Orthognathic Surgery: A Prospective, Comparative, Randomized Study between Amoxicillin-Clavulanic Acid and Penicillin. J Med Association Thailand 11: 1726-31, 2008.
Advertisements
No advertisements will be used for enrollment in this study.
Additional Considerations
Funding has been provided by the Canadian Association of Oral and Maxillofacial Surgery.
Background, Rationale and Statement of Research Question(s):
Surgical site infection is a potential problem with any surgical procedure. Surgical procedures done through the oral cavity are at a higher risk due to the presence of bacterial pathogens. Orthognathic surgery, involves incising through oral mucosa and creating osteotomies in underlying bony structures. Of the potential complications that can arise from this surgery, post operative infection (POI) is the most common. POI can have a significant impact on surgical outcomes and are associated with an increased cost to the health care system. The literature is quite clear on the benefits of presurgical prophylactic antibiotics in reducing the rate of post operative surgical site infections.1 Currently there is conflicting literature as to the recommended length patients should receive antibiotics during the postoperative course, and the majority of studies have small sample sizes.2,3
Orthognathic surgery is considered a clean-contaminated surgery with a suspected POI rate of 10-15%.2 In 1999 Bentley et. al conducted a randomized control trial comparing 1day vs 5day regimen of antibiotics following orthognathic surgery.4 This trial was stopped due to the drastic difference seen between the two groups, 6.7% in the 5 day course compared with 60% seen in the 1 day group.4 This data varies greatly from the rates of infection that the investigators have seen in their department using a 1 day course of antibiotics. Chow et al. in 2007 did a retrospective chart review of complications seen in orthognathic surgery. They found the rate of infection was significantly decreased by continuing antibiotics in the post operative course when compared to using only one prophylactic dose. They found the infection rates to be 17.3% with a single preoperative IV dose, 5.1% with a pre-operative dose and 2 days post-operative, and 7.7% with a pre-operative dose and 3 days of post-operative antibiotics.5 They also found no significant difference in rates of infection comparing 2 days and up to 14 days.5 A meta-analysis by Danda et al. in 2011 found that a regimen consisting of a single dose of preoperative antibiotics followed with an extended term postoperatively is the most effective in decreasing surgical site infections. They found the incidence decreased by 3.2 times, with the greatest effect noted with administration for 2 days.2 Even in this meta-analysis the average number of patients in each of the 8 studies was 67, with the total number of patients included being 532.2 This shows the need for randomized controlled studies with large sample sizes in order to determine the best antimicrobial regimen for these patients. The majority of studies investigating the rates of infection in orthognathic surgery use penicillin as the antibiotic of choice due to its spectrum of coverage for oral microbes and it is reasonably tolerated by patients.2,4-8 In the investigators department cefazolin is the antibiotic of choice and lower rates of infection have been observed compared to penicillin. The investigators suspect the lower rates of infection with cefazolin is due to the increased gram negative coverage and better resistance to beta lactamases. This has influenced the investigators decision to use first generation cephalosporins instead of penicillin as first line antimicrobials. In patients allergic to penicillin, clindamycin is used. The criteria for diagnosis of infection will follow the CDC guidelines for SSI. The primary outcome is to determine if there is any benefit to extending antimicrobials in the postoperative course following orthognathic surgery. Secondary outcomes include comparing the rates of infection between cefazolin/cephalexin groups and the clindamycin groups, and the rate of infection with different surgical procedures.
Currently at the CDHA the standard perioperative antimicrobial regimen for orthognathic surgery patients is one preoperative prophylactic dose of 2g of IV cefazolin followed by 1g IV every 8 hrs for 3 doses. Patients with an allergy to penicillin receive one preoperative prophylactic dose of IV Clindamycin 600mg, followed by 600mg IV every 8 hrs for 3 doses.
The investigators plan to conduct a double blind randomized controlled trial comparing the effect of a single day of post operative antibiotics with an extended 3 day course of antimicrobials on the infection rate. Both groups will receive an IV prophylactic dose followed by 3 IV doses postoperatively. Group 1 will then receive PO antibiotics for 2 subsequent days following IV treatment, and group 2 will receive a PO placebo.
A placebo will be used in order to blind the two groups so that the patient, surgeon and investigators are not aware of which patients are receiving the extended regimen of antibiotics. This will avoid potential bias in the patient report of symptoms or side effects, and the surgeon's bias in diagnosis of surgical site infection.
Subject Selection:
All patients over the age of 16 years undergoing orthognathic surgery at the QEII VG hospital are eligible to participate in the study. All surgeons operating at the VG site have been asked to include their patients in this study. These include patients undergoing either isolated Lefort I osteotomy, bilateral sagittal split osteotomies, functional genioplasties, or any combination of the three procedures. Wisdom teeth, if present, will also be extracted at the time of the surgery. Exclusion criteria include use of antibiotics in the past 2 weeks, active oral or odontogenic infection, significant medical condition, or if the patient is immunocompromised. All patients will have history and physical examination, CBC, INR/PTT, electrolytes as well as a radiographic evaluation prior to surgery. A power analysis was done to determine the required patient sample size for this study. This was done using a 5% change in infection as clinically significant and type I error of 0.05 with 0.90 power. The sample size required would be 397 patients. The investigators would like to enroll as many as possible over the next 2 years and anticipate to enroll approximately 500 patients. Study enrollment will finish in 2 years time from starting date, unless required sample size has not been met at which time it may be decided to extend length.
Research Plan:
All patients enrolled in the study will receive the standard preoperative IV prophylactic antibiotic, followed by 3 IV doses postoperatively. The patients will be randomly allocated to either the placebo or the antibiotic group at their presurgical assessment appointment. This allocation will be done by a clinical nurse, patients will be given a study patient number and handed a envelope from a folder that has been mixed sufficiently, inside this envelope will be a paper with an A or B denoting to the Shoppers Drug Mart pharmacy on the main floor of the VG hospital to dispense the according bottle they are to receive. This will be recorded beside their study number, and not be unblinded until the study is concluded. Blinding is important to avoid bias in assessment of infection by the surgeons, and to avoid bias in reporting of symptoms of either infection or side effects from the antibiotics. Following the completion of the IV antibiotic regimen, group 1 will receive oral cephalexin or clindamycin four times per day for 2 days and group 2 will receive a placebo four times per day for 2 days. All patients will also be sent home with specific oral hygiene instructions in addition to chlorhexidine 0.12% rinse to be used for 2 weeks postoperatively.
Patients will be assessed for signs of infection and recovery progress daily during hospital stay and during regular recall visits at 2 weeks and 4 weeks following discharge. There is no additional time requirements or cost to the patient by participating in this study. The diagnosis of infection will be made according to the CDC criteria of surgical site infection which include: purulent drainage, wound culture for known pathogen, at least one of signs or symptoms of infection (pain, tenderness, localized swelling, redness or heat)1.
The patient may withdrawl from the study at any time. A patient may be removed from the study if there is a significant change in the patients medical condition. An interm review of the rates of infection will be done and if the data demonstrates an increase risk to patients participating in study, the study will be stopped and unblinded.
All adverse events, serious adverse events, adverse drug reations will be reported to the Oral Maxillofacial Surgery Department and the patient will be assessed by the resident or attending surgeon.
Analysis of Data
All of the data will be organized and pooled according to each specific group. Following the study the blinding will be undone, and the primary outcome investigating the rate of infection will be analyzed in each of the four groups, 1 day cefazolin, 3 day cefazolin/cephalexin, 1 day clindamycin, 3 day clindamycin. Each of the 1 day groups will be compared and the 3 day groups in order to determine if the length of time on antibiotic has an effect on the rate of infection. Then the 1 day group and 3 day groups will be compared for the different type of antibiotic to see if the type of antibiotic has bearing on the length required. These comparisons will be done using a chi squared formula to look for statistical significance. This analysis will also be used to compare rates of infection between the type of surgical procedures done. Each of the groups will also be analyzed for possible confounding factors including time of surgery, age, sex, and oral hygiene status.
Confidentiality
All data will be kept secure by the research team by storing it in a locked office filing cabinet, or on a password protected file on the secured hospital network. Only the investigators, and research nurse will have access to this data. Following the study, the data will be kept in a locked cabinet for at least 25 years as required by law.
Harms
As all patients will receive the standard current protocol used at the investigators center, with the test group receiving an addition 2 days of antibiotics. The risks associated with participation in the study are those seen from prolonged antibiotic use. These include allergic reactions ranging from rash to anaphylaxis, toxic reactions to kidney, liver, gastrointestinal and secondary infections from candida or resistant pathogens. If anaphylaxis occurs normal protocol will be followed for treatment and monitoring. In the event of other adverse events from the antibiotic it will be stopped and any secondary infections will be treated appropriately. In the case of post operative infection this will be treated with a 10 day course of appropriate antibiotics.
Benefits
Overall the benefit of this study is to determine the ideal length of postoperative antibiotics in preventing post operative surgical site infections in patients undergoing orthognathic surgery. The group receiving an extended course of antibiotics potentially may have a lower rate of infection. Conversely, the placebo group may have the same rate of infection and avoid potential side effects of extended antibiotic treatment.
Disclosure of Any Financial Compensation
There will be no monetary compensation for participation in this study. Either the antibiotic or the placebo will be provided to the patient at no cost.
References
1. National Center for Infectious Diseases, Mangram AJ, Horan TC, Pearson ML, et. al. Guideline for Prevention of Surgical Site Infection, 1999. Infection Control and Hospital Epidemiology, 20:4:247- 278, 1999
2. Danda AK, Ravi P. Effectiveness of Postoperative Antibiotics in Orthognathic Surgery: A Meta-Analysis. J Oral Maxillofacial Surgery 69:2650-2656,2011
3. Tan SK, Lo J, Zwahlen RA. Perioperative Antibiotic Prophylaxis in Orthognathic Surgery: A Systematic Review and Meta-Analysis of Clinical Trials. Surg Oral Med Oral Pathology Oral Radiology Endodontics 112:19-27, 2011
4. Bentley KC, Head TW, Aiello GA. Antibiotic Prophylaxis in Orthognathic Surgery: A 1-Day Versus 5-Day Regimen. J Oral Maxillofacial Surgery 57:226-230.1999
5. Chow LK, Singh B, et al. Prevalence of Postoperative Complications After Orthognathic Surgery: A 15year Review. J Oral Maxillofacial Surgery 65:984-992, 2007
6. Ruggles JE, Hann JR, Antibiotic Prophylaxis in Intraoral Orthognathic Surgery. J Oral Maxillofacial Surgery 42:797-801, 1984.
7. Fridrich KL, Partnoy BE, Zeitler DL. Prospective analysis of Antibiotic Prophylaxis for Orthognathic Surgery. International Journal Adult Orthodontic and Orthognathic Surgery 9:129-131, 1994
8. Jansisyanont P, Sessirisombat S, Sastravaha P, Bamroong P, Antibiotic Prophylaxis for Orthognathic Surgery: A Prospective, Comparative, Randomized Study between Amoxicillin-Clavulanic Acid and Penicillin. J Med Association Thailand 11: 1726-31, 2008.
Advertisements
No advertisements will be used for enrollment in this study.
Additional Considerations
Funding has been provided by the Canadian Association of Oral and Maxillofacial Surgery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Dentofacial Deformity
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
PREVENTION
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cefazolin, Cephalexin, Clindamycin
Group will be receiving 1 day of IV cefazolin or clindamycin followed by 2 days of oral cephalexin or clindamycin
Clindamycin will be used in patients with allergy
Group Type
ACTIVE_COMPARATOR
Cefazolin, Cephalexin, Clindamycin
Intervention Type
DRUG
cefazolin, clindamycin, placebo
Group will receive 1 day IV cefazolin, or clindamycin followed by 2 days of oral placebo
clindamycin will be used if patient has allergy
Group Type
PLACEBO_COMPARATOR
Cefazolin, Cephalexin, Clindamycin
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cefazolin, Cephalexin, Clindamycin
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Ancef, Keflex, Dalacin C
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* over 16 years old undergoing orthognathic surgery
Exclusion Criteria
* Use of antibiotics in last 2 weeks, active oral or odontogenic infection, significant medical condition, immunocompromised
Minimum Eligible Age
16 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Atlantic Center for Oral and Maxillofacial Surgery
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Curtis Gregoire
Dr. Curtis Gregoire Oral and Maxillofacial Surgeon
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Victoria General Hospital
Halifax, Nova Scotia, Canada
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Canada
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999 Apr;27(2):97-132; quiz 133-4; discussion 96.
Reference Type
BACKGROUND
Danda AK, Ravi P. Effectiveness of postoperative antibiotics in orthognathic surgery: a meta-analysis. J Oral Maxillofac Surg. 2011 Oct;69(10):2650-6. doi: 10.1016/j.joms.2011.02.060. Epub 2011 May 6.
Reference Type
BACKGROUND
Tan SK, Lo J, Zwahlen RA. Perioperative antibiotic prophylaxis in orthognathic surgery: a systematic review and meta-analysis of clinical trials. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Jul;112(1):19-27. doi: 10.1016/j.tripleo.2010.07.015. Epub 2010 Dec 17.
Reference Type
BACKGROUND
Bentley KC, Head TW, Aiello GA. Antibiotic prophylaxis in orthognathic surgery: a 1-day versus 5-day regimen. J Oral Maxillofac Surg. 1999 Mar;57(3):226-30; discussion 230-2. doi: 10.1016/s0278-2391(99)90664-x.
Reference Type
BACKGROUND
Chow LK, Singh B, Chiu WK, Samman N. Prevalence of postoperative complications after orthognathic surgery: a 15-year review. J Oral Maxillofac Surg. 2007 May;65(5):984-92. doi: 10.1016/j.joms.2006.07.006.
Reference Type
BACKGROUND
Ruggles JE, Hann JR. Antibiotic prophylaxis in intraoral orthognathic surgery. J Oral Maxillofac Surg. 1984 Dec;42(12):797-801. doi: 10.1016/0278-2391(84)90348-3.
Reference Type
BACKGROUND
Fridrich KL, Partnoy BE, Zeitler DL. Prospective analysis of antibiotic prophylaxis for orthognathic surgery. Int J Adult Orthodon Orthognath Surg. 1994;9(2):129-31.
Reference Type
BACKGROUND
Jansisyanont P, Sessirisombat S, Sastravaha P, Bamroong P. Antibiotic prophylaxis for orthognathic surgery: a prospective, comparative, randomized study between amoxicillin-clavulanic acid and penicillin. J Med Assoc Thai. 2008 Nov;91(11):1726-31.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACOMFS-Orthognathic
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Or v IV Antibiotics for Infection
NCT04723940
UNKNOWN
PHASE3
Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection
NCT00187759
COMPLETED
NA
Efficacy Assessment of Two Antibiotic Prophylaxis Regimens in Oral and Maxillofacial Trauma Surgery
NCT01993134
UNKNOWN
PHASE2
Antibiotic Prophylaxis in Orthopaedic Traumatology
NCT00610987
COMPLETED
NA
Antibiotic Prophylaxis in Clean Surgery. Impact on Surgical Site Infection
NCT03595852
COMPLETED
NA
Antibiotic Use in Facial Fracture Post Injury
NCT04925531
RECRUITING
A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting
NCT04516148
COMPLETED
PHASE4
Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery
NCT04580472
RECRUITING
PHASE4
Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis
NCT01029782
COMPLETED
PHASE2
Local Antibiotics for Breast Implants
NCT04731025
RECRUITING
PHASE3
Oral-only Antibiotics for Bone and Joint Infections in Children
NCT04563325
COMPLETED
PHASE4
Use of Preoperative and Postoperative Antimicrobial Treatment
NCT04707092
UNKNOWN
PHASE4
Microbiome and Association With Implant Infections
NCT05020574
RECRUITING
PHASE2
Antibiotic Prophylaxis for Revision, Clean Head and Neck Surgery
NCT01980082
COMPLETED
PHASE4
Antibiotic Prophylaxis in Prosthetic Breast Reconstructions
NCT02012517
UNKNOWN
PHASE4
Perspectives on Prophylactic Antibiotic Use in Dermatologic Surgery
NCT04150523
COMPLETED
Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens
NCT03560232
TERMINATED
PHASE4
Antibiotic Prophylaxis in Pediatric Open Fractures
NCT06055712
ENROLLING_BY_INVITATION
PHASE4
Surgical Site Infection and Antibiotic Use Study
NCT04631185
COMPLETED
NA
Wound Infections Following Implant Removal
NCT02225821
COMPLETED
PHASE4
P.Acnes Colony Count Following Subdermal Cefazolin
NCT03853096
UNKNOWN
EARLY_PHASE1
Impact of Pharmaceutical Interviews Regarding the Management of Adverse Effects Related to the Antibiotic Therapy Used to Treat Osteoarticular Infections During Return Home
NCT05248490
COMPLETED
NA
Antibiotic Prophylaxis for Simple Hand Lacerations
NCT01155154
TERMINATED
NA
Prophylactic Antibiotic in Subtalar Fusion Surgery
NCT06527989
NOT_YET_RECRUITING
PHASE2/PHASE3
Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation
NCT03224299
COMPLETED
PHASE2